

IA Diagnostic-Vaccine



Unmet need:

There are limited antimicrobial drugs available to treat invasive fungal diseases, especially *Aspergillus fumigatus* infection of immunocompromised individuals (i.e., invasive pulmonary aspergillosis (IPA)), which is increasing in frequency due to the use of immunomodulatory drugs used to treat susceptible individuals. Moreover, diagnosis of fungal disease in general, and that caused by the opportunistic pathogen *A. fumigatus* in particular, is especially problematic

Our Solution:

An integrated development programme could deliver a commercial high sensitivity, competitive TAFC-ELISA; a qualitative TAFC-specific lateral flow test (LFT) test for the rapid detection of TAFC in clinical specimens; and high value TAFC-specific monoclonal IgG and TAFC analog-protein conjugates for vaccine-challenge studies and cognate vaccine challenge studies

Given the current state of flux in the fungal diagnostic market, and the absence of any safe and effective vaccine to prevent, and possibly treat the infection

in humans- and animals- it is contended that this platform technology offers significant, integrated and complementary first-mover advantage. From a therapeutic perspective, the absence of a vaccine in the marketplace represents a major USP for a new product. The key diagnostic USP is that it is proposed to develop the first IVD to detect a virulence-associated biomarker, with associated price premium, to diagnose IPA/CPA

Development Stage:

Stage 4: Development.

What is sought:

Licence or Commercial partners for collaboration

Intellectual Property:

Patent application

Contact:

Paul.Tyndall@mu.ie
+353 1 708 6872

Development Stages of Opportunities

